Form 8-K - Current report:
SEC Accession No. 0000950170-24-113241
Filing Date
2024-10-07
Accepted
2024-10-07 16:33:30
Documents
11
Period of Report
2024-10-03
Items
Item 2.01: Completion of Acquisition or Disposition of Assets

Document Format Files

Seq Description Document Type Size
1 8-K inzy-20241003.htm   iXBRL 8-K 41754
  Complete submission text file 0000950170-24-113241.txt   159852

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inzy-20241003.xsd EX-101.SCH 25818
13 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20241003_htm.xml XML 4880
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

EIN.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 241358211
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)